Efficacy of As-needed versus Regular Use of MP-AzeFlu in Moderate-to-severe Allergic Rhinitis: A randomized controlled trial MPAzeFlu Azelastine Hydrochloride and Fluticasone Proprionate rTNSS RCQ36 GRADE Rhinomanometry Moderate-to-severe Allergic Rhinitis
Conditions
Interventions
2 week of regular used MPAzeFlu then 4 week of as needed used of MPAzeFlu,2 week of regular used MPAzeFlu then 4 week of regular used of MPAzeFlu
Experimental Drug,Experimental Drug
AsneededMPAzeFlu,RegularusedofMPAzeFlu
Sponsors
Department of Otolaryngology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - >18 years old - baseline VAS score > 5 - not have used oral or intranasal antihistamines, anti-leukotrienes, inhaled or intranasal corticosteroids, or oral and intranasal decongestants within two weeks prior to the study.
Exclusion criteria
Exclusion criteria: rhinosinusitis, nasal polyps, or significant septal deviation. Those who have used oral corticosteroids within the past 30 days or have a history of current or prior immunotherapy are also ineligible. Additionally, patients with known allergies to MP-AzeFlu, as well as pregnant or breastfeeding individuals, are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean difference of TNSS in between as-needed used and regular used 6 weeks data record | — |
Secondary
| Measure | Time frame |
|---|---|
| mean difference of individual nasal symptom scores in between as-needed used and regular used 6 weeks Data record,mean difference of VAS in between as-needed used and regular used 6 weeks data record,mean difference of RCQ-36 between as-needed use and regular use 6 weeks data record,mean difference of PNIF between as-needed use and regular use 6 weeks data record | — |
Countries
Thailand
Contacts
Public ContactSaroj Suriwongse
Faculty of medicine ramathibodi hospital, mahidol university
Outcome results
None listed